VR Interventions in Obesity and Eating Disorders: A Systematic Review

Introduction to VR Interventions in Obesity and Eating Disorders

Obesity and eating disorders (EDs) represent significant public health challenges, contributing to high morbidity and mortality rates globally. A recent systematic review published in May 2026 evaluates the potential of immersive virtual reality (VR) interventions in addressing these conditions. The review highlights promising effects on clinical and biomarker outcomes but emphasizes the need for larger, standardized trials to confirm efficacy and understand underlying mechanisms.

Mechanisms and Context of VR Interventions

The review, conducted following PRISMA 2020 guidelines, analyzed studies from databases like PubMed, Web of Science, and PsycINFO up to April 2025. It included studies that employed immersive VR interventions targeting obesity or EDs, reporting at least one biomarker-domain outcome. The interventions varied, with VR-enhanced cognitive-behavioral therapy (VR-CBT) showing potential in weight-loss maintenance for obesity and reductions in body image disturbance for EDs. VR-based exercise interventions also demonstrated short-term reductions in BMI and body weight.

Meta-analyses of randomized controlled trials (RCTs) revealed a significant pooled effect of VR on anthropometric outcomes, with VR-CBT showing a numerically larger effect. In EDs, VR cue-exposure therapy was linked to decreased binge and purge frequency, while eye-tracking measures indicated attentional biases toward disorder-relevant cues. Autonomic and endocrine markers suggested VR's ability to elicit measurable psychophysiological responses.

Implications for Policy and Future Research

The findings of this review could inform future clinical applications and therapeutic strategies in public health contexts. VR interventions may offer a novel approach to addressing obesity and EDs, potentially enhancing existing treatment modalities. However, the conclusions are constrained by small sample sizes and heterogeneity within the interventions and outcome definitions. The limited randomized evidence base, particularly in EDs, underscores the need for larger biomarker-integrated trials with standardized measurement protocols and longer follow-up periods.

Risks and Unknowns

While the review presents promising outcomes, several risks and unknowns remain. The variability in intervention types and outcome measures poses challenges in drawing definitive conclusions about VR's efficacy. Additionally, the small sample sizes limit the generalizability of the findings. Future research must address these limitations to establish robust evidence for VR interventions in obesity and EDs. Ethical considerations, such as ensuring patient safety and data privacy in VR environments, must also be prioritized.

Looking Forward

As the field of VR interventions continues to evolve, researchers and clinicians have the opportunity to explore innovative therapeutic strategies for obesity and EDs. Larger, well-designed trials are essential to confirm the efficacy of VR interventions and to elucidate the mechanisms through which they exert their effects. Collaboration between researchers, clinicians, and policymakers will be crucial in translating these findings into effective public health interventions.